STORZ MEDICAL’s MAGNETOLITH receives CE approval

In February 2020, STORZ MEDICAL has received the CE approval for the MAGNETOLITH^® system, which is the successor of the CELLACTOR^® MT1. Extracorporeal Magnetotransduction Therapy (EMTT^®) with the MAGNETOLITH^® opens up new possibilities in regeneration and rehabilitation. The areas of application include diseases of the musculoskeletal system such as lower back pain and tendinopathies of the rotator cuff or Achilles tendon. The non-invasive, outpatient therapy is virtually free of side effects.

EMTT^® differs from general forms of magnetic field therapy or PEMF due to the high oscillation frequency of 100 – 300 kHz. This property enables a high penetration depth (18 cm) and a large range of indications.

Treatment with the MAGNETOLITH^® system is comfortable and straightforward:

• The patient does not have to undress
• Effective fatigue-free work for the user
• Applicator positioning by hand or with the flexible holding arm
• A treatment session takes between 5 – 20 minutes depending on the indication
• Adjustable frequency (up to 10 pulses/s)

MAGNETOLITH / Static treatment of shoulder with holding arm

EMTT^® Highlights

• High-frequency magnetic field (100 – 300 kHz)
• Continuous and reliable operation due to the water-cooled applicator
• Click & connect mechanism for a flexible applicator positioning
• Simple plug in & plug out to change applicator
• Integrated touch display to adjust energy level, frequency & pulse rate

Typical indications of EMTT^®
Musculoskeletal diseases

• Degenerative joint diseases
  Signs of wear and tear, e.g. arthrosis (knee, hip, hands, shoulder, elbow), herniated disc, spondylarthrosis
• Pain therapy
  (Chronic) pain, e.g. back pain, lumbalgia, tension, radiculopathies
• Sport injuries
  (Chronic) inflammation of tendons and joints, tendon overload syndrome, osteitis pubis

Further information on the new MAGNETOLITH^® is available on our website